Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Oregovomab

Oregovomab Am J Cancer 2003; 2 (2): 135-136 GUEST COMMENTARIES 1175-6357/03/0002-0135/$30.00/0 © Adis Data Information BV 2003. All rights reserved. sponses are thought to be responsible for an antitumor effect. As such, the agent may be functioning as a vaccine against the tumor, A Viewpoint by Jonathan S. Berek and if proven to be effective could serve as a useful adjunct to Division of Gynecologic Oncology, David Geffen School of chemotherapy for ovarian cancer. Medicine at UCLA, Los Angeles, California, USA In an effort to utilize this antibody in a strategy to prevent Oregovomab is a murine monoclonal antibody that is directed relapse in women who achieved a complete clinical remission toward CA125, a high molecular weight glycoprotein that has following their initial surgery and chemotherapy, a randomized, been associated with 80–90% of epithelial ovarian cancers. The placebo-controlled clinical trial was conducted. The drug was very majority of women (>70%) with ovarian cancer have advanced well tolerated. The subset of patients that appeared to have a stage disease at the time of diagnosis. prolonged time to disease progression (compared with While most patients with ovarian cancer have tumors that are highly chemosensitive and achieve clinical remissions, the majori- placebo-treated patients) http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png American Journal of Cancer Springer Journals

Oregovomab

Abstract

Am J Cancer 2003; 2 (2): 135-136 GUEST COMMENTARIES 1175-6357/03/0002-0135/$30.00/0 © Adis Data Information BV 2003. All rights reserved. sponses are thought to be responsible for an antitumor effect. As such, the agent may be functioning as a vaccine against the tumor, A Viewpoint by Jonathan S. Berek and if proven to be effective could serve as a useful adjunct to Division of Gynecologic Oncology, David Geffen School of chemotherapy for ovarian cancer. Medicine at UCLA, Los Angeles,...
Loading next page...
 
/lp/springer-journals/oregovomab-JLdgw09mfz
Publisher
Springer Journals
Copyright
Copyright © 2003 by Adis Data Information BV
Subject
Pharmacy; Pharmacy
ISSN
1175-6357
DOI
10.2165/00024669-200302020-00006
Publisher site
See Article on Publisher Site

Abstract

Am J Cancer 2003; 2 (2): 135-136 GUEST COMMENTARIES 1175-6357/03/0002-0135/$30.00/0 © Adis Data Information BV 2003. All rights reserved. sponses are thought to be responsible for an antitumor effect. As such, the agent may be functioning as a vaccine against the tumor, A Viewpoint by Jonathan S. Berek and if proven to be effective could serve as a useful adjunct to Division of Gynecologic Oncology, David Geffen School of chemotherapy for ovarian cancer. Medicine at UCLA, Los Angeles, California, USA In an effort to utilize this antibody in a strategy to prevent Oregovomab is a murine monoclonal antibody that is directed relapse in women who achieved a complete clinical remission toward CA125, a high molecular weight glycoprotein that has following their initial surgery and chemotherapy, a randomized, been associated with 80–90% of epithelial ovarian cancers. The placebo-controlled clinical trial was conducted. The drug was very majority of women (>70%) with ovarian cancer have advanced well tolerated. The subset of patients that appeared to have a stage disease at the time of diagnosis. prolonged time to disease progression (compared with While most patients with ovarian cancer have tumors that are highly chemosensitive and achieve clinical remissions, the majori- placebo-treated patients)

Journal

American Journal of CancerSpringer Journals

Published: Aug 10, 2012

There are no references for this article.